The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog is intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Support this site

    If you found the information here helpful, please consider supporting this site.If you found the information here helpful, please consider supporting this site.

  • Recent Posts

  • Recent Comments

    No benefit from milk thistle to treat hepatitis C

    The botanical extract silymarin (milk thistle,) has anti-oxidant, anti-inflammatory, and immunomodulatory properties and is used by patients with chronic liver disease.

    Researchers throughout the U.S. collaborated to evaluate the response to high doses of silymarin taken by mouth on disease activity in patients with chronic hepatitis C. The results were presented during the American Association for the Study of Liver Diseases November Annual Meeting.

    First, the details.

    • 154 patients with chronic hepatitis C infection and alanine transaminase (ALT) activity greater than 65 IU/L were randomly assigned to a treatment group.
      • 1 of 2 doses of a standardized silymarin preparation (Legalon® 140, Rottapharm Madaus) at 420 or 700 mg administered orally 3 times daily for 24 weeks.
        • These doses are 4.5 to 7.5 times higher than customary.
      • Placebo
    • At the end of therapy, blood activity of ALT less than 45 IU/L (within normal range) or ALT less than 65 IU/L (less than 1.5 x upper limit of normal) was considered a success provided this was at least a 50% decline from starting values.
    • Changes in ALT and HCV RNA during treatment, and adherence to treatment based on dose counts, and silymarin blood levels were also examined.

    And, the results.

    • Regardless of treatment, the average decline in ALT at the end of treatment did not differ significantly.
    • Only 6 participants (2 in each group) were considered successfully treated.
    • Over 90% of participants met or exceeded an 80% adherence to study medications, despite the substantial pill burden (15 capsules per day).
    • Analysis of ALT activity did not demonstrate significant changes in ALT activity among treatments.
    • Side effects were not different between silymarin and placebo.

    The bottom line?

    The authors concluded, “Although well tolerated, oral silymarin administered at higher than customary doses did not significantly alter biochemical markers of disease activity in patients with chronic hepatitis C who had failed prior treatment with interferon-based regimens.”

    Back in 2007, a friend asked me to look into CAM treatments for liver disease. I did, but found little to support milk thistle — the most often discussed CAM treatment. Now, for patients with chronic hepatitis C fail prior interferon-based treatment there’s even less.

    11/28/11 18:32 JR

    Leave a Comment

    XHTML: Line-breaks are automatic. Available tags are <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>